Regarding the outcome of SARS-CoV-2 infection, ≤30 days PSO (T1), patients with COVID-19 admitted to the ICU, our analyses revealed a distinct pattern of antibody production, with higher levels of anti-NP IgG and IgA in the survival group, but anti-Spike and anti-RBD IgA had higher levels in the fatal group. This evidence concerns the gene CD79A and COVID-19.